Phage display for discovery of anticancer antibodies
Polina V Istomina, Andrey A. Gorchakov, Chatchanok Paoin, Montarop Yamabhai
Abstract
Antibodies and antibody-based immunotherapeutics are the mainstays of cancer immunotherapy. Expanding the repertoire of cancer-specific and cancer-associated epitopes targetable with antibodies represents an important area of research. Phage display is a powerful approach allowing the use of diverse antibody libraries to be screened for binding to a wide range of targets. In this review, we summarize the basics of phage display technology and highlight the advances in anticancer antibody identification and modification via phage display platform. Finally, we describe phage display-derived anticancer monoclonal antibodies that have been approved to date or are in clinical development. • Concise review of principles of phage display technology. • Various approaches for library construction and selection strategies. • Antibody engineering via phage display technology. • Ab formats, guided selection, humanization, affinity maturation, Ab developability. • Current landscape of anticancer antibodies derived from phage display technology.